Presenting longitudinal data

被引：2

作者：

不详

机构：

来源：

CURRENT PROBLEMS IN CANCER | 2005年 / 29卷 / 06期

关键词：

D O I：

10.1016/j.currproblcancer.2005.09.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：296 / 305

页数：10

共 10 条

[1]

Albert PS, 1999, STAT MED, V18, P1707, DOI 10.1002/(SICI)1097-0258(19990715)18:13<1707::AID-SIM138>3.0.CO

[2]

2-H

[3]

Diggle P., 1993, Analysis of longitudinal data

[4]

Fairclough DL, 1997, STAT MED, V16, P1197, DOI 10.1002/(SICI)1097-0258(19970615)16:11<1197::AID-SIM531>3.0.CO

[5]

2-9

[6]

Sloan J A, 2004, J Biopharm Stat, V14, P73, DOI 10.1081/BIP-120028507

[7]

SLOAN JA, 2005, DELATIONSHIP QUALITY

[8]

SLOAN JA, 2005, OUTCOMES ASSESSMENT, P362

[9]

SMITH D, 2005, PHARMASUG P

[10] Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy [J].

Witzig, TE ;

Silberstein, PT ;

Loprinzi, CL ;

Sloan, JA ;

Novotny, PJ ;

Mailliard, JA ;

Rowland, KM ;

Alberts, SR ;

Krook, JE ;

Levitt, R ;

Morton, RF .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2606-2617

← 1 →